ES414 could be therapeutic for castrate-resistant prostate cancer

A new molecule is being developed as a therapeutic for prostate cancer.

Researchers have suggested ES414 is being developed as a potential therapeutic for castrate-resistant prostate cancer.
The lead bispecific ADAPTIRTM (Modular Protein Technology) molecule ES4141 was presented at the American Association for Cancer Research annual meeting, Emergent BioSolutions Inc revealed.
As Emergent explained, the molecule was constructed through the use of its ADAPTIRTM technology platform.
It was shown to redirect T-cell cytotoxicity towards cancer cells expressing PSMA, and it is now being developed as a possible therapeutic for castrate-resistant prostate cancer.
Indeed, a statement from Emergent outlined how ES414 was able to inhibit subcutaneous tumour outgrowth in the presence of human T- cells in two mouse models of prostate cancer.

Dr Jane Gross commented: "We were excited to present the results of these studies and were very pleased with the interest these data received at the meeting."
In the US alone, around 230,000 new cases of prostate cancer occur every year, making it the most prevalent cancer among American men.